Background and Objectives: C6-ceramide analog LCL29 was recently shown to improve the cure rates of mouse tumors treated by photodynamic therapy (PDT), but the mechanism underlying the therapeutic gain remains unclear. Since LCL29 is a pro-apoptotic agent, the main objective of the present study was
Cancer therapy via ceramide-mediated apoptosis
- Publisher
- Elsevier Science
- Year
- 1997
- Tongue
- English
- Weight
- 106 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0167-5699
No coin nor oath required. For personal study only.
โฆ Synopsis
It ,p ~lccesS 0, Mure cf PROW
๐ SIMILAR VOLUMES
A novel pathway termed the sphingomyelin cycle has been identified whereby membrane sphingomyelin is hydrolyzed in response to multiple extracellular stimuli (such as tumor necrosis factor a ) which cause activation of regulated sphingomyelinases. The product, ceramide, has emerged as a second messe
Numerous new photosensitizers are now in various stages of trials demonstrating the broad applicability of Photodynamic therapy (PDT). However, only a handful of photosensitizers have received regulatory approval. Lack of effective photosensitizers has become a major limit for extensive application